Now picture microcin B17, an antibiotic that kills E. coli bacteria. Before being activated, it lies embedded in a structure called a prodrug, like the core of an unsharpened “molecular pencil.”
Todd B. Bates reports that now, for the first time, scientists at Rutgers University–New Brunswick and other institutions have discovered a “molecular pencil sharpener” that chews away its outer coating to release the powerful antibiotic.
Their discovery opens the door to finding new antibacterial agents and drugs to fight toxins.
The scientists, whose discovery was published in the journal Structure, studied TldD and TldE bacterial proteins involved in making microcin B17.
Many bacterial cells make inactive compounds called prodrugs – precursors that turn into drugs in the body, Severinov said.
“It’s like a future drug and when the need arises and when the going gets tough, the drug is activated and it’s like a toxic warhead that gets exported outside the cell and kills its harmful neighbors,” he said.
The prodrug examined by the scientists is like a stick with two parts, he said. The core part is the toxic warhead. A “leader” is on the other end and prevents the warhead from functioning until the right time.
“TldD, the protein we studied, has a hole in it just like in an old pencil sharpener, where the prodrug is fed into,” Severinov said. “The sharpener adds the last finishing touch, chewing the leader, activating the toxic warhead and kicking it out of the cell. So it’s almost like having an ability to produce toxic compounds, including antibiotics, a la carte when you need them.”
Tld genes are common in bacteria, suggesting that they play an important function in bacterial physiology, the study says. That might include a role in protein quality control and activating different natural products including antibiotics, such as microcin B17.
“Every bacterial genome sequenced to date has Tld genes,” Severinov said. “Nobody knew what they do, and now we know what they do in one case, and we think that similar functions activate the production of bioactive compounds used by other bacteria as antibiotics or toxins.”
Some toxins could be used in a beneficial way, he noted. For example, people have been using bacterial toxins to kill insects for decades. And when bacteria produce toxins that harm humans, drugs that inhibit Tld and fight such bacteria could be developed.
The scientists speculate that their findings could lead to future applications in the protein engineering and synthetic biology fields.